Ignite Creation Date:
2025-12-24 @ 10:08 PM
Ignite Modification Date:
2026-01-01 @ 11:45 AM
Study NCT ID:
NCT07103135
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-17
First Post:
2025-04-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling
Sponsor:
University of Minnesota
Organization:
Study Overview
Official Title:
Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of accelerated intermittent theta burst stimulation (aiTBS) targeting personalized nodes within the somato-cognitive action network (SCAN) and action motor network (AMN) for the treatment of chronic pain. The study will employ Thompson Sampling, a Bayesian reinforcement learning algorithm, to optimize stimulation site selection based on individual response patterns. This approach has the potential to revolutionize pain management by improving treatment accessibility through shortened timelines, addressing individual variations in pain networks through precision targeting, and potentially achieving more robust pain relief through accelerated neuroplasticity.
The specific aims of the study are:
1. To establish the relationship between SCAN and AMN connectivity and cognitive- affective pain symptoms.
2. To evaluate the efficacy of Thompson Sampling-optimized aiTBS across SCAN and AMN on affective and sensorimotor pain dimensions.
3. To identify fMRI connectivity biomarkers predictive of treatment response and remission.
The specific aims of the study are:
1. To establish the relationship between SCAN and AMN connectivity and cognitive- affective pain symptoms.
2. To evaluate the efficacy of Thompson Sampling-optimized aiTBS across SCAN and AMN on affective and sensorimotor pain dimensions.
3. To identify fMRI connectivity biomarkers predictive of treatment response and remission.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: